Paula Ragan compensation by year
X4 Pharmaceuticals Summary Compensation Table · all 9 fiscal years held| Component | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Salary | $364,000 | $380,000 | $492,276 | $543,400 | $562,126 | $583,481 | $620,053 | $654,156 | $420,170 |
| Bonus | $0 | $0 | $0 | $0 | $0 | $58,773 | $0 | $0 | $0 |
| Stock awards | $0 | $0 | $824,938 | $1,690,827 | $1,258,272 | $476,904 | $1,035,784 | $312,962 | $1,081,575 |
| Option awards | $303,422 | $407,577 | $893,460 | $0 | $0 | $2,432,049 | $0 | $857,686 | $0 |
| Non-equity incentive | $89,180 | $133,000 | $286,000 | $271,700 | $309,330 | $308,557 | $375,132 | $305,818 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $576 | $450 | $1,177 | $7,605 | $11,600 | $12,769 | $13,792 | $14,419 | $1,138,824 |
| Total | $757,178 | $921,027 | $2,497,851 | $2,513,532 | $2,141,328 | $3,872,533 | $2,044,761 | $2,145,041 | $2,640,569 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: X4 Pharmaceuticals, Inc DEF 14A filed March 20, 2026, accession 0001501697-26-000031, and prior-year filings. Open the filing on EDGAR.
How this page was built: the X4 Pharmaceuticals, Inc filed document, accession 0001501697-26-000031. Every figure is read from that document and cited to the page and table it appears in. Filed March 20, 2026.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 339,880 | $248,112 | — |
| Option | 1,189,578 | — | $0.92 |
| Option | 1,146,112 | — | $1.80 |
Per the Outstanding Equity Awards at Fiscal Year-End table in X4 Pharmaceuticals, Inc's FY2024 proxy; value at the fiscal year-end close, as the company printed it.
X4 Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Adam Craig | Executive Chairman | $6,705,205 |
| John Volpone | President and Chief Operating Officer | $6,667,487 |
| David Kirske | Chief Financial Officer, Treasurer and Corporate Secretary | $4,599,266 |
| Paula Ragan · this page | Former President and Chief Executive Officer | $2,640,569 |
Board service
X4 Pharmaceuticals board · FY2021–FY2024How this board is paid
Company policy: X4 Pharmaceuticals pays directors a $40,000 cash retainer. As stated in X4 Pharmaceuticals's FY2024 proxy.
The full X4 Pharmaceuticals compensation record
free company briefThis page is one person within X4 Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order X4 Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are X4 Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order XFOR
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.